Bilivist

   
Google
 
Web NewDrugInformation.com

Bilivist


Drug - Bilivist
The trade name of the product as shown on the labeling.

Dosage - CAPSULE; ORAL
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Ipodate Sodium
Multiple ingredients are in alphabetical order.

Strength - 500MG
The potency of the active ingredient(s), Ipodate Sodium. May repeat for multiple part products.

Applicant - BERLEX
The firm name holding legal responsibility for Bilivist. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 087768
The FDA assigned number to Bilivist. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Bilivist. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Aug 11, 1982
The date Bilivist was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Bilivist. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - DISCN
The group or category of approved drugs Bilivist is in. Format is RX, OTC, DISCN.

Applicant Full Name - Berlex Inc
The full name of the firm holding legal responsibility for the new application of Bilivist.

Bilivist